Topic

Onivyde (irinotecan liposome)

A collection of 28 issues

How to Get Onivyde (Irinotecan Liposome) Covered by Cigna in Illinois: Prior Authorization, Appeals, and Renewal Guide

Quick Answer: Cigna requires prior authorization for Onivyde (irinotecan liposome) with specific clinical documentation: confirmed metastatic pancreatic adenocarcinoma, prior gemcitabine-based therapy failure (for second-line), ECOG performance status, and oncologist attestation. Submit via Cigna's Onivyde PA form with 5-day standard review. If denied, file internal appeal within 180 days,
6 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Cigna in Ohio: Forms, Appeals, and Approval Timeline

Answer Box: Quick Path to Onivyde Coverage Cigna requires prior authorization for Onivyde (irinotecan liposome) in Ohio. Most approvals need: metastatic pancreatic cancer diagnosis, prior gemcitabine or fluoropyrimidine failure, ECOG 0-2 performance status, and adequate organ function. Submit the Cigna Onivyde PA form via fax (855-840-1678) or CoverMyMeds. Standard review
5 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Appeal Guide with Forms and Timelines

Quick Answer: Getting Onivyde Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield plans in Pennsylvania require prior authorization for Onivyde (irinotecan liposome) as a specialty cancer treatment. Submit PA requests through your plan's provider portal with pathology-confirmed metastatic pancreatic adenocarcinoma, ECOG performance status 0-1,
6 min read

Getting Onivyde (Irinotecan Liposome) Covered by Blue Cross Blue Shield of North Carolina: Complete PA Guide and Appeals Process

Answer Box: Quick Path to Onivyde Coverage Blue Cross Blue Shield of North Carolina requires prior authorization for Onivyde (irinotecan liposome), typically approved for FDA-indicated NALIRIFOX regimen in first-line metastatic pancreatic cancer. Your oncologist submits PA documentation including confirmed diagnosis, performance status, and treatment rationale. If denied, file internal appeal
6 min read

Humana's Coverage Criteria for Onivyde (Irinotecan Liposome) in New Jersey: What Counts as "Medically Necessary"?

Answer Box: Humana Onivyde Coverage in New Jersey Onivyde (irinotecan liposome) is covered by Humana Medicare Advantage with prior authorization for FDA-approved pancreatic cancer indications. Medical necessity requires: ECOG performance status 0-1, documented diagnosis, and appropriate line of therapy (first-line NALIRIFOX or second-line post-gemcitabine). Fastest approval: Submit complete PA documentation
5 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Aetna CVS Health in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Onivyde Approved by Aetna CVS Health in California Onivyde (irinotecan liposome) requires prior authorization from Aetna CVS Health in California for pancreatic cancer treatment. The fastest path to approval involves submitting a complete PA request with documented medical necessity, prior therapy failures, and performance status. If denied,
6 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Cigna in Michigan: Prior Authorization, Appeals, and Cost Assistance

Answer Box: Getting Onivyde (Irinotecan Liposome) Covered by Cigna in Michigan Quick Path to Approval: Cigna requires prior authorization for Onivyde through Express Scripts/Accredo specialty pharmacy. Your oncologist submits documentation including diagnosis, prior gemcitabine failure, lab results, and ECOG performance status. Standard review takes 2 business days; expedited review
6 min read